Description

15,45,000 equity shares of Novelix Pharmaceuticals Limited (Scrip Code 536565) issued at Rs. 20/- on preferential basis pursuant to warrant conversion, listed and permitted to trade from November 27, 2025.

Summary

NovelixPharmaceuticals Limited (Scrip Code: 536565) has listed 15,45,000 new equity shares of Rs. 10/- each issued at a premium of Rs. 10/- (total issue price Rs. 20/-) on the BSE. These shares were allotted on August 14, 2025, to Promoters and Non-Promoters on a preferential basis pursuant to conversion of warrants. The shares will be available for trading from November 27, 2025, and rank pari-passu with existing equity shares.

Key Points

  • Total new shares listed: 15,45,000 equity shares of Rs. 10/- each
  • Issue price: Rs. 20/- per share (including premium of Rs. 10/-)
  • Basis of issue: Preferential allotment pursuant to warrant conversion
  • Allottees: Promoter and Non-Promoter categories
  • Distinctive Numbers: 12935001 to 14480000
  • ISIN: INE314I01036
  • Trading commencement: November 27, 2025
  • Shares rank pari-passu with existing equity shares

Regulatory Changes

No regulatory changes announced in this circular.

Compliance Requirements

  • Trading members are informed to note the listing of these new securities
  • Lock-in restrictions apply to the allotted shares as specified
  • The securities will be available for trading subject to lock-in provisions

Important Dates

  • Allotment Date: August 14, 2025
  • Trading Commencement: November 27, 2025
  • Lock-in Expiry (6,45,000 shares): June 30, 2026
  • Lock-in Expiry (9,00,000 shares): June 30, 2027

Lock-in Details

  • 9,00,000 shares (Dist. Nos. 12935001 to 13835000) locked-in until June 30, 2027
  • 6,45,000 shares (Dist. Nos. 13835001 to 14480000) locked-in until June 30, 2026

Impact Assessment

Market Impact: Low. This is a routine listing of shares pursuant to warrant conversion on preferential basis. The quantum of shares (15.45 lakh) represents capital expansion for the company.

Liquidity Impact: Limited immediate impact on liquidity as all 15,45,000 shares are subject to lock-in restrictions ranging from 6 months to 1.5 years from the notice date.

Investor Impact: Existing shareholders should note the dilution in equity share capital. New shares rank equally with existing shares in all respects including dividend rights.

Impact Justification

Routine listing notice for preferential allotment of shares pursuant to warrant conversion. Limited market impact as it affects a single company's expanded share capital with lock-in restrictions.